Enter company name or symbol or keyword from report title or report description. You can also use our advanced search option to further filter your results.
Register NowLogin to receive $10 worth of FREE credit. This offer is valid for limited time.
984 (79%) - Correct 255 (21%) - Incorrect
Explanation
Recent News on Covered Stocks
VVUS
THLD
CORT
CTIC
NGSX
Regeneron Pharmaceuticals Inc. (REGN) - Upcoming Event - March 2012
Zaltrap for Hormone-Refractory Prostate Cancer/HRPC (Final Phase III VENICE trial data)
Final Phase III VENICE trial data of Zaltrap for Hormone-Refractory Prostate Cancer (HRPC)
- Price: $20.00 Add to cart Mail to friend Add to favorite
VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
Specific theme-based reports at a value price
©Copyright 2012 New Bio Medicine, LLC. All Right Reserved.
